Patients with rheumatoid arthritis often develop methotrexate-associated lymphoproliferative disorders (MTX-LPD) during MTX treatment. MTX-LPD occasionally regresses spontaneously after simply discontinuing MTX treatment. In patients without spontaneous regression, additional chemotherapy is required to avoid disease progression. However, the differences between spontaneous and non-spontaneous regression have yet to be elucidated. To clarify the factors important for spontaneous regression, we analyzed the clinicopathological features of 51 patients with rheumatoid arthritis who developed MTX-LPD (diffuse large B-cell lymphoma [DLBCL]-type [n = 34] and classical Hodgkin lymphoma [CHL]-type [n = 17]). We examined the interval from MTX discontinuation to the administration of additional chemotherapy. The majority of DLBCL-type MTX-LPD patients (81%) exhibited remission with MTX discontinuation alone. In contrast, the majority of CHL-type MTX-LPD patients (76%) required additional chemotherapy. This difference was statistically significant (P = 0.001). However, overall survival was not significantly different between DLBCL-type and CHL-type (91% vs 94%, respectively; P > 0.05). Thus, the morphological differences in the pathological findings of MTX-LPD may be a factor for spontaneous or non-spontaneous regression after discontinuation of MTX.
M ethotrexate (MTX) is an anti-cancer agent that is classified as an anti-folate and is used as an anti-rheumatic drug. MTX-associated lymphoproliferative disorders (MTX-LPD) is a lymphoproliferative disease or lymphoma in patients treated with MTX for autoimmune diseases, such as rheumatoid arthritis (RA).
(1) MTX-LPD was first reported in 1991 and was subsequently established as a disease concept owing to the reported increase in incidence with the increasing use of MTX for the treatment of RA. (2) MTX-LPD is classified as "other iatrogenic immunodeficiency-associated LPDs" in the 4th edition of the World Health Organization classification. (2) MTX-LPD have various histopathological features. Among patients treated with MTX, the most commonly reported cases are diffuse large B-cell lymphoma (DLBCL; 35-60%) and classical Hodgkin lymphoma (CHL; 12-25%)-types. (2) There are no histological differences compared with the lymphomas of RA patients who develop non-MTX-LPD. (2, 3) Although the developmental mechanism of MTX-LPD is poorly understood, it is assumed that immune disorders in patients with RA and immunosuppression associated with MTX might contribute to the development of MTX-LPD. In the majority of patients with MTX-LPD, activation of the Epstein-Barr virus (EBV) has been detected, (3, 4) EBV-positive patients, and some other patients with MTX-LPD, experience spontaneous regression of their lesions after simply discontinuing MTX treatment. (5) (6) (7) In patients with MTX-LPD that do not spontaneously regress, additional chemotherapy is required to avoid disease progression. (7) However, the differences between spontaneous and non-spontaneous regression have yet to be elucidated.
To clarify the factors important for spontaneous regression, we examined the histopathological features, IGH gene rearrangements, EBV-encoded small RNA (EBER)-positive rates, and the clinical course of RA patients who developed DLBCLtype or CHL-type MTX-LPD.
Patients and Methods
Patients. We analyzed the clinicopathological features of 51 patients who had been diagnosed with MTX-LPD (DLBCLtype [n = 34] and CHL-type [n = 17]) and whose records were selected from pathology files in the Department of Pathology at Okayama University (Okayama, Japan). We excluded patients with polymorphous-type MTX-LPD.
All patients received low-dose MTX, and 17 patients (33%) received MTX with prednisolone. Five DLBCL-type and 4 CHL-type MTX-LPD patients were treated with MTX in combination with other disease-modifying anti-rheumatic drugs (e.g., infliximab, etanercept, adalimumab, and bucillamine). In this study, 19 DLBCL-type (56%) and 12 CHL-type MTX-LPD patients (71%) were included in the analysis of MTX administration. The median treatment duration was 119 (range, months.
This study was approved by the Institutional Review Board of Okayama University (Okayama, Japan).
Clinical data. Data regarding the Eastern Cooperative Oncology Group performance status and clinical stage (CS) were collected from medical records.
Histological examination and in situ hybridization. Specimens were fixed in 10% formaldehyde and embedded in paraffin. Three-micrometer-thick sections were cut from the paraffinembedded tissue blocks and stained with hematoxylin and eosin.
Paraffin sections of each tissue sample were used for immunohistochemical staining with antibodies to CD3 (clone: LN10, 1:200; Novocastra Laboratories, Ltd., Newcastle upon Tyne, UK), CD5 (clone: 4C7, 1:100; Novocastra Laboratories, Ltd.), CD10 (clone: 56C6, 1:100; Novocastra Laboratories, Ltd.), CD15 (clone: Carb-3, 1:50; DAKO, Glostrup, Denmark), CD20 (clone: L26, 1:100; DAKO), CD30 (clone: Ber-H2, 1:40; DAKO), EBV nuclear antigen 2 (EBNA2) (clone: PE2, 1:100; Abcam, Cambridge, MA, USA), EBV latent membrane protein 1 (LMP-1) (clone: CS1-4, 1:50; Novocastra Laboratories, Ltd.), and Ki-67 (clone: MIB-1, 1:2500; DAKO). Staining was performed using the automated Bond Max Stainer (Leica Biosystems, Wetzlar, Germany).
The EBV was detected by in situ hybridization for EBER using the automated Bond Max Stainer (Leica Biosystems).
IGH gene rearrangement analysis. We scraped sections from the tumor area and placed them in 19 AmpliTaq Gold Buffer (Applied Biosystems, Inc., Foster City, CA, USA). DNA was extracted by incubating at 94°C for 45 min, using the automated Thermocycler GeneAmp PCR System 9700 (Applied Biosystems, Inc.). DNA was quantified using the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). IGH gene rearrangement analysis was performed as previously described. (8) The following primers were used in this study:
, and JH consensus primer (5 0 -CTTACCTGAGGAGACGGTGA CC-3 0 ). The JH consensus primer was fluorescently labeled. All primers were purchased from Sigma-Aldrich (SigmaAldrich Japan, Tokyo, Japan). PCR products were analyzed using an ABI PRISM 310 Genetic Analyzer with GeneScan Analysis and GeneMapper software (Applied Biosystems, Inc.). IGH gene rearrangements were analyzed and evaluated using the BIOMED-2 protocol. (8) If the waveform of the PCR product could be confirmed, even by a small amount, this finding was interpreted as polyclonal expression. If a peak was not visible (e.g., due to sample condition) then these samples were deemed to have undetectable expression.
Statistical analyses. Differences between DLBCL-type and CHL-type MTX-LPD were determined using Student's t and v 2 tests. A P < 0.05 was considered statistically significant. Overall survival was defined as the time from the date of diagnosis of a MTX-LPD to the date of death or last follow-up. Progression-free survival was defined as the time from the date of diagnosis of a MTX-LPD to the date of commencing chemotherapy or the date of death or last follow-up. The follow-up duration was calculated as the time from the date of diagnosis of a MTX-LPD to the date of death from any cause or last follow-up. The duration from the date of diagnosis of a MTX-LPD to the date of commencing chemotherapy was determined. Survival curves were generated using the Kaplan-Meier method. All statistical analyses were conducted using SPSS for Windows software version 14.0 (SPSS Inc., Chicago, IL, USA).
Results
Comparison of the clinicopathological features between patients with DLBCL-type and CHL-type MTX-LPD. Of the 51 patients with a MTX-LPD, 34 patients (67%) had a DLBCLtype MTX-LPD and 17 patients (33%) had a CHL-type MTX-LPD. The median age of the entire cohort was 67 (range, 45-84) years, and the median age did not differ between the MTX-LPD subtypes ( Table 1 ). The male-tofemale ratio of the entire cohort was 14:37 and the proportion of female patients was high for both MTX-LPD subtypes.
Reduced hemoglobin levels of <10.5 g/dL were observed in 30% (9/30) patients with a DLBCL-type MTX-LPD and 46% (6/13) patients with a CHL-type MTX-LPD. A reduction in the total lymphocyte count was observed in 34% (10/29) patients with a DLBCL-type MTX-LPD and 23% (3/13) patients with a CHL-type MTX-LPD. The median soluble interleukin 2 receptor value was 2,748 IU/mL for the DLBCLtype MTX-LPD (n = 30) and 2,450 IU/mL for the CHL-type MTX-LPD (n = 15).
The Eastern Cooperative Oncology Group performance status was not significantly different between the MTX-LPD subtypes (P > 0.05). Twelve patients with a DLBCL-type MTX-LPD and five patients with a CHL-type MTX-LPD had an Eastern Cooperative Oncology Group performance status of ≥2. CS was also not significantly different between the MTX-LPD subtypes (P > 0.05). Twenty-five patients with a DLBCL-type MTX-LPD and 13 patients with a CHL-type MTX-LPD had a CS of ≥3 (Table 1) .
Of the 17 patients with a CHL-type MTX-LPD, seven patients (41%) had extranodal lesions in organs and tissues, such as the brain, lungs, kidneys, liver, and bone marrow.
Histopathological classification. DLBCL-type MTX-LPD. Atypical lymphoid cells were large and revealed monomorphic proliferation. The rates of positive immunohistochemical staining for CD3, CD5, CD10, and CD20 were 0% (0/34), 0% (0/26), 5% (1/22), and 88% (30/34), respectively ( Fig. 1) . A high Ki-67 labeling index of >30% (i.e., a high Ki-67 labeling index) was observed for all of the cases with a DLBCL-type MTX-LPD. The EBER-positive rate was 82% (28/34; Table 1 ). CHL-type MTX-LPD. Hodgkin and Reed-Sternberg cells were observed in a cellular background rich in non-neoplastic small lymphocytes, histiocytes, and eosinophils. In the Hodgkin and Reed-Sternberg cells, the rates of positive immunohistochemical staining for CD3, CD15, CD20, CD30, EBNA2, and LMP-1 were 0% (0/16), 60% (9/15), 29% (5/17), 100% (17/17), 0% (0/11), and 62% (8/13), respectively (Fig. 2) . The EBER-positive rate was 82% (14/ 17; Table 1 ).
The EBV latent infection type was analyzed in the CHLtype MTX-LPD cases. A type I infection (EBER-positive, LMP-1-negative, and EBNA2-negative) was observed in two cases, a type II infection (EBER-positive, LMP-1-positive, and EBNA2-negative) in six cases, and a type III infection (EBERpositive, LMP-1-positive, and EBNA2-positive) in 0 cases. The EBV latent infection type was not available for the remaining nine cases ( Table 2) .
IGH gene rearrangement. IGH gene rearrangements were analyzed in 36 cases (DLBCL-type MTX-LPD [n = 27] and CHL-type MTX-LPD [n = 9]). In the DLBCL-type MTX-LPD, monoclonal rearrangements were detected in two cases (7%) and polyclonal rearrangements were detected in 17 cases (63%). In the CHL-type MTX-LPD, polyclonal rearrangements were detected in five cases (56%). IGH gene rearrangements were undetectable in the remaining cases.
Clinical course of patients with MTX-LPD after discontinuing MTX treatment. CHL-type MTX-LPD. In all patients, the administration of MTX had been discontinued at the time of MTX-LPD diagnosis (Table 2) . In four patients, the lesions were reduced and were controllable after the discontinuation of MTX treatment. Another seven patients showed regrowth after reduction of the lesions and additional chemotherapy was required. Relapse occurred in seven patients with a CHL-type MTX-LPD. The median duration until relapse was 6.4 months. Discontinuation of MTX treatment was ineffective in six patients. These patients received chemotherapy for the CHL. Therefore, additional chemotherapy was required in a total of 13 patients (76%). Of the 13 patients who required additional chemotherapy, 12 patients exhibited complete remission after chemotherapy; one patient died of bacterial pneumonia during chemotherapy (Table 3) . DLBCL-type MTX-LPD. Among the 34 patients with a DLBCL-type MTX-LPD, MTX was discontinued in 27 patients at the time of MTX-LPD diagnosis. In 22 patients (81%), remission of the lesions occurred after MTX was discontinued and additional chemotherapy was unnecessary. Only one patient exhibited regrowth after reduction of the lesion. The duration until relapse was 10.7 months. This patient died without receiving chemotherapy after relapse. Four patients required additional chemotherapy after the discontinuation of MTX. Of these, three patients exhibited complete remission after chemotherapy and one patient died of therapy-related acute myeloid leukemia. The attending physician initiated chemotherapy using the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) regimen or similar.
For five patients, chemotherapy was initiated at the same time as the MTX-LPD was diagnosed. Of these, four patients exhibited complete remission after chemotherapy and one patient died of the MTX-LPD.
Two patients with a MTX-LPD were diagnosed at autopsy. The cause of death was the MTX-LPD and gastrointestinal bleeding (Table 4) .
Progression-free survival analysis of patients with MTX-LPD.
The progression-free survival differed significantly between the two MTX-LPD subtypes (12.1 vs 6.4 months for the DLBCLtype and CHL-type, respectively; P = 0.001) (Fig. 3) . The two patients diagnosed at autopsy and the five patients who commenced chemotherapy at the time the MTX-LPD was diagnosed were excluded from this analysis.
Overall survival analysis of patients with MTX-LPD. The median overall survival did not differ significantly between the two MTX-LPD subtypes (P > 0.05; Fig. 4) . The two patients diagnosed at autopsy were also excluded from this analysis.
The median follow-up durations were 16.9 and 36.0 months for patients with a DLBCL-type and CHL-type MTX-LPD, respectively.
Discussion
In this study, we investigated the clinicopathological differences between patients with DLBCL-type (n = 34) and CHLtype (n = 17) MTX-LPD. Overall, more female patients developed MTX-LPD, which might be related to the fact that RA is more common among women.
In previous studies, (2, 3, 7, 9, 10) lesion reduction was observed in 25-60% of the total number of patients after MTX was discontinued, and subsequent regrowth was reported in 18-45% of patients. Comparatively, lesion reduction was observed in 34 patients (77%) in the present study, and regrowth was confirmed in eight patients (24%). Of the eight patients with tumor regrowth, only the patient with a DLBCL-type MTX-LPD died. The overall survival rates were comparable between the DLBCL-type and CHL-type MTX-LPD and despite a high CS the overall survival rates were good. These results were consistent with those of previous reports. (7, 9, 11) The immune deficiency owing to MTX administration helps to explain these findings, and the clinical course of the DLBCL-type MTX-LPD differs from that of non-MTX-associated DLBCL. In the present study, the median follow-up durations of the DLBCLtype and CHL-type MTX-LPD were 16.9 and 36.0 months, respectively. In several previously published reports, (10) the mean follow-up duration of MTX-LPD patients was 24.3 (range, 8-60) months. Given that there were patients who suffered a relapse after remission was achieved by the discontinuation of MTX, we think that further long-term observations are required. In this study, the majority of the 51 patients had a high CS; the CS ≥ 3 in 25 patients (74%) with DLBCL-type MTX-LPD and 13 patients (76%) with CHL-type MTX-LPD. In addition, a large proportion of patients had extranodal lesions. Of the 17 patients with CHL-type MTX-LPD, seven patients (41%) had extranodal lesions in organs and tissues, such as the brain, lungs, kidneys, liver, and bone marrow. Non-MTX-associated Overall survival of patients with diffuse large B-cell lymphoma-type or classical Hodgkin lymphoma-type methotrexate-associated lymphoproliferative disorders. The difference in overall survival was not statistically significant (P = 0.408).
